Guggenheim Reiterates Buy Rating on Oracle (June 5)

Analyst: John DiFucci 2 min read Reproduced verbatim
Rating
Buy
Unchanged
Target
$400
Unchanged
Upside
+245%
ORCL at $116 today
Guggenheim and Oracle logos

What the analyst said

Guggenheim analyst John DiFucci reiterated a Buy rating and $400.00 price target on Oracle (NYSE: ORCL).

“It’s been a volatile 9-month period for ORCL’s stock, but several positive developments have materialized in recent months, namely the $45-$50B debt/equity raise and OpenAI’s $120B funding round, which should help assuage investor concerns around the data center build-out.

IaaS revenue and FY27 capex guidance are the biggest investor questions heading into the print, and we believe the setup for F4Q IaaS revenue is reasonable (it requires a similar amount of New IaaS ARR coming online as the past two quarters which gives us confidence in ORCL’s ability to do so), while we believe capex guidance should come in around $75B—at least that’s what it could be without BYOC considerations that we’re not privy to.

Elevated capex the next two years (we’re modeling $85B in FY28) would lead to significantly negative free cash flow with FY27 being the trough before turning into a cash flow waterfall in FY29 based on ORCL’s RPO of $553B.

We continue to see potential risk to consensus Cloud gross margin due to IaaS mix and depreciation ramp, but less risk to operating margin given operating expense efficiencies.

On RPO, we believe expansion with blue-chip customers would be more positively received by investors and credit rating agencies than additional model training company backlog.

That said, we do not expect a change to long-term targets, even with the potential for incremental deals signed in the quarter and a newly appointed CFO.

Lastly, our partner checks indicate a strong close to FY26, with the largest partner exceeding expectations, and three others meeting expectations.

Strength was attributed to Middle East outperformance, Industry Solution momentum, and Cloud Database traction.

Buy rated ORCL continues to be our Best Idea, which we view as a “Decade Stock” based on superior technology and execution. We maintain our Price Target of $400.

ORCL will report F4Q earnings on 6/10 post-close.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Where the price stands

ORCL trades at $116. The 22 analysts who set a target in the last 3 months range from $155 to $400, with a median of $233. This $400 target is 72% above the median, the highest on the Street.

Since the note ORCL has moved −51% (from $236). 12-month window: day 155 of 365, closes on June 5, 2027.

Track record

This callOpen: ORCL has not reached $400 yet. This 12-month target is scored on June 5, 2027.

Firm track recordGuggenheim: 29% of its 7 targets at least a year old were reached within 12 months. Accuracy ranking →

Guggenheim on Oracle

Guggenheim price targets on Oracle

7 calls from February 2, 2026 to October 29, 2026. The target stayed at $400. The rating stayed Buy.

Guggenheim targetORCL share price
  1. October 29, 2026Kept the $400 targetBuy$400
  2. September 11, 2026Kept the $400 targetBuy$400
  3. September 8, 2026Kept the $400 targetBuy$400
  4. July 23, 2026Kept the $400 targetBuy$400
  5. June 11, 2026Kept the $400 targetBuy$400
  6. June 5, 2026 This noteKept the $400 targetBuy$400
  7. February 2, 2026Earliest call shownBuy$400
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.